415 related articles for article (PubMed ID: 19886884)
21. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
[TBL] [Abstract][Full Text] [Related]
23. Transungual delivery of ketoconazole using novel lacquer formulation.
Hafeez F; Hui X; Chiang A; Hornby S; Maibach H
Int J Pharm; 2013 Nov; 456(2):357-61. PubMed ID: 24029171
[TBL] [Abstract][Full Text] [Related]
24. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
Schaller M; Sigurgeirsson B; Sarkany M
Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
[TBL] [Abstract][Full Text] [Related]
25. A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.
Ghannoum M; Long L; Kunze G; Sarkany M; Osman-Ponchet H
Mycoses; 2019 Jun; 62(6):494-501. PubMed ID: 30667544
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly.
Reinel D; Clarke C
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():44-9. PubMed ID: 1458665
[TBL] [Abstract][Full Text] [Related]
27. Potential of Naftifine Application for Transungual Delivery.
Šveikauskaitė I; Briedis V
Molecules; 2020 Jul; 25(13):. PubMed ID: 32635240
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
[TBL] [Abstract][Full Text] [Related]
29. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis.
Piraccini BM; Iorizzo M; Lencastre A; Nenoff P; Rigopoulos D
Dermatol Ther (Heidelb); 2020 Oct; 10(5):917-929. PubMed ID: 32705532
[TBL] [Abstract][Full Text] [Related]
30. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
31. Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment.
Gaballah EY; Borg TM; Mohamed EA
Drug Deliv; 2022 Dec; 29(1):3304-3316. PubMed ID: 36372978
[TBL] [Abstract][Full Text] [Related]
32. Ciclopirox nail lacquer: a brush with onychomycosis.
Gupta AK
Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
[TBL] [Abstract][Full Text] [Related]
33. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Subissi A; Monti D; Togni G; Mailland F
Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
[TBL] [Abstract][Full Text] [Related]
34. Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect on pig skin.
Ceschin-Roques CG; Hänel H; Pruja-Bougaret SM; Luc J; Vandermander J; Michel G
Skin Pharmacol; 1991; 4(2):89-94. PubMed ID: 1831626
[TBL] [Abstract][Full Text] [Related]
35. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
Monti D; Mazzantini D; Tampucci S; Vecchione A; Celandroni F; Burgalassi S; Ghelardi E
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332076
[TBL] [Abstract][Full Text] [Related]
36. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
Bhatt V; Pillai R
J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
[TBL] [Abstract][Full Text] [Related]
37. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
38. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
Vejnovic I; Huonder C; Betz G
Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of topical antifungal products in an in vitro onychomycosis model.
Sleven R; Lanckacker E; Delputte P; Maes L; Cos P
Mycoses; 2016 May; 59(5):327-30. PubMed ID: 26857689
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
